JP2025509568A - 新生血管加齢性黄斑変性を治療する方法 - Google Patents

新生血管加齢性黄斑変性を治療する方法 Download PDF

Info

Publication number
JP2025509568A
JP2025509568A JP2024554787A JP2024554787A JP2025509568A JP 2025509568 A JP2025509568 A JP 2025509568A JP 2024554787 A JP2024554787 A JP 2024554787A JP 2024554787 A JP2024554787 A JP 2024554787A JP 2025509568 A JP2025509568 A JP 2025509568A
Authority
JP
Japan
Prior art keywords
weeks
dose
regimen
patient
vegf antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024554787A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509568A5 (https=
Inventor
デイビッド ケアンズ，ジェフリー
ムリュコフ，ズファー
オルガ，ウフク
ピジョレット，エティエンヌ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2025509568A publication Critical patent/JP2025509568A/ja
Publication of JP2025509568A5 publication Critical patent/JP2025509568A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/102—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for optical coherence tomography [OCT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2024554787A 2022-03-17 2023-03-16 新生血管加齢性黄斑変性を治療する方法 Pending JP2025509568A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263320796P 2022-03-17 2022-03-17
US63/320,796 2022-03-17
US202263386380P 2022-12-07 2022-12-07
US63/386,380 2022-12-07
PCT/IB2023/052565 WO2023175549A1 (en) 2022-03-17 2023-03-16 Methods for treating neovascular age-related macular degeneration

Publications (2)

Publication Number Publication Date
JP2025509568A true JP2025509568A (ja) 2025-04-11
JP2025509568A5 JP2025509568A5 (https=) 2026-03-25

Family

ID=85873755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024554787A Pending JP2025509568A (ja) 2022-03-17 2023-03-16 新生血管加齢性黄斑変性を治療する方法

Country Status (5)

Country Link
US (1) US20250197486A1 (https=)
EP (1) EP4493589A1 (https=)
JP (1) JP2025509568A (https=)
TW (1) TW202337496A (https=)
WO (1) WO2023175549A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1802334E (pt) 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
TW202116802A (zh) * 2019-09-13 2021-05-01 瑞士商諾華公司 治療眼部疾病之方法

Also Published As

Publication number Publication date
EP4493589A1 (en) 2025-01-22
TW202337496A (zh) 2023-10-01
US20250197486A1 (en) 2025-06-19
WO2023175549A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
US20260098085A1 (en) Methods for treating age-related macular degeneration
AU2021286278C1 (en) Methods for treating ocular diseases
US20250197486A1 (en) Methods for treating neovascular age-related macular degeneration
CN116710137A (zh) 用于在治疗眼部疾病的方法中使用的vegf拮抗剂
JP7828274B2 (ja) 眼疾患を治療するための方法
US20230416351A1 (en) Vegf antagonist for use in methods for treating ocular diseases
RU2776850C2 (ru) Способы лечения глазных заболеваний

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260316